A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs including (i) a Rho kinase inhibitor selected from the group consisting of (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and 1-(5-isoquinolinesulfonyl)-homopiperazine, or a salt thereof and (ii) a prostaglandin which is latanoprost or a salt of latanoprost, and (iii) optionally a pharmaceutically acceptable carrier. A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs comprising (i) a Rho kinase which is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide or a slat thereof and (ii) a prostaglandin which is isopropyl unoprostone or a salt thereof, and (iii) optionally a pharmaceutically acceptable carrier.
